Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Corporate Presentation

Updated as of June 11, 2018

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 – April 30, 2018

FOURTH QUARTER February 1, 2018 – April 30, 2018
  • Consolidated net sales amounted to TSEK 843 compared to TSEK 44 in the fourth quarter the previous year
  • Operating loss was T...
Read more

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer.
Read more

Nexttobe Extends Loan to Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company. The cur...
Read more
To news archive